2024年9月30日 · Alfonso Savastano, MD, PhD spoke about the SING-IMT implant during his interview with Ophthalmology Times Europe, which took place at the EURETINA 2024 meeting held in Barcelona, Spain, on September 19-22, 2024.. Video Transcript: Editor's note: The below transcript has been lightly edited for clarity.

2025年1月24日 · Investigators from the Cleveland Clinic Cole Eye Institute, Cleveland, reported the results of a study that identified macular structural and vascularity changes in adults who had been born prematurely, 1 according to first author Jacob T. Cox, MD, MPhil. Cox and colleagues reported these results after conducting a retrospective review of adults who were patients at the Cleveland Clinic July ...

2024年10月31日 · Valerie Biousse, MD, from the Emory University in Atlanta, Georgia, shared insights on how ocular imaging in the emergency department can provide timely, accurate diagnosis while also benefiting the on-call ophthalmologists.

2024年9月23日 · At this year's EURETINA Congress, we met with Aleksandra Rachitskaya, MD, FASRS, a member of the Modern Retina editorial advisory board, to talk about her event highlights. In this video, she discusses the Vit-Buckle Society's symposia on challenging retinal surgical videos, her presentation on the impact of home OCT data in management of neovascular AMD, and more.

2024年11月13日 · Imaging techniques to differentiate papilledema from ODD . Several different OCT measurements have been postulated to help differentiate ODD/pseudopapilledema from papilledema, such as RNFL thickness, macular ganglion cell–inner plexiform layer thickness, forward displacement of the Bruch membrane, and subretinal hyporeflective spacer.

2024年11月19日 · Astellas Pharma Inc. announced the United States Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for avacincaptad pegol intravitreal solution (IZERVAY).

2024年11月27日 · Arshad Khanani, MD, MA, FASRS, Director of Clinical Research at Sierra Eye Associates, Reno, NV, presented positive data from the phase 2 fellow eye sub-study evaluating the subretinal delivery of ABBV-RGX-314 in patients with bilateral wet age-related macular degeneration (wet AMD) at the 2024 American Academy of Ophthalmology (AAO) meeting.

2024年11月26日 · Patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) treated with investigational oral therapy gildeuretinol (ALK-001) showed a statistically significant reduction in the GA lesion growth rate of 15.3% vs. placebo from 6 to 24 months (p=0.047). 1 In addition to the reduction in lesion growth, gildeuretinol also demonstrated a statistically significant ...

2025年1月3日 · The Data and Safety Monitoring Board (DSMB) for the OCU410 ArMaDa clinical trial convened and approved continuation of the second phase of the Phase 1/2 study.

2024年12月26日 · In 2024, Modern Retina covered news from around the globe on clinical trials, technology in retina, trending topics in ophthalmology, and retina conferences. Let’s look back on some of the top stories of the year as we gear up for an incredible 2025. GA and AMD. Age-related macular degeneration (AMD) and geographic atrophy (GA) continue to be major areas of development as researchers seek ...